Alumis
Grace Halteh has over 25 years of work experience in various roles related to quality management, regulatory affairs, and compliance. Grace is currently serving as the Vice President of Quality at Alumis, a position they started in September 2022. Previously, they held the same role at Arcellx, Inc. from August 2021 to September 2022.
Before that, Grace worked as the Executive Director of Development Operations Quality Management at Exelixis from October 2018 to August 2021. Grace also served as the Executive Director of GCP & GLP QA and Compliance at Nektar Therapeutics from April 2017 to October 2018.
Their experience also includes roles at Jazz Pharmaceuticals, Genentech - Roche, Janssen Alzheimer Immunotherapy - A Johnson & Johnson Subsidiary, Elan Pharmaceuticals, and Oral-B, The Gillette Company. Grace has demonstrated expertise in project management, clinical operations, and quality systems throughout their career.
Grace Halteh has a Bachelor of Science (B.S.) degree in Cell and Molecular Biology. Grace also holds a Master of Science (M.S.) degree in Systems Management. In addition, they have obtained a Project Management Professional (PMP) certification from PMI.
Alumis
2 followers
At Alumis, our goal is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights we derive from powerful data analytics to select the right target, right molecule, right indication, right patient, and right endpoint resulting in optimized outcomes for patients. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. Incubated by Foresite Labs, Alumis is led by a team of deeply experienced professionals who are devoted to transforming the lives of patients with immune-mediated diseases by developing a pipeline of transformative therapies.